JACC. Case reports · 2025
Multisystemic, Possibly Familial Sarcoidosis Ameliorated by an mTOR Inhibitor.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brown Roxxy, Macrohon-Sabaitue Sharon, Specterman Mark, Asimaki Angeliki
Аннотация
BACKGROUND: Sarcoidosis is an inflammatory, multisystemic, potentially life-threatening disease with a precise etiology that remains largely unknown. It is characterized by granuloma formation in various organs that can lead to permanent organ scarring and failure. Currently there is no curative treatment. Traditional drug interventions target reduction of inflammation and symptom control and have not shown definitive proof of a survival benefit.
CASE SUMMARY: We present the cases of a mother and son treated for chronic aggressive multiorgan sarcoidosis with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor. Both patients experienced a marked reversal of inflammation in their respective affected organs coupled with profound symptom relief.
CONCLUSIONS: Inhibition of mTOR may be an effective, safe treatment option for patients with conventional-drug-resistant forms of systemic sarcoidosis.
CASE SUMMARY: We present the cases of a mother and son treated for chronic aggressive multiorgan sarcoidosis with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor. Both patients experienced a marked reversal of inflammation in their respective affected organs coupled with profound symptom relief.
CONCLUSIONS: Inhibition of mTOR may be an effective, safe treatment option for patients with conventional-drug-resistant forms of systemic sarcoidosis.